Odyssey Health, Inc. 8-K

What Happened
Odyssey Health, Inc. (ODYY) filed an 8-K reporting that on May 6, 2026 NeuRX Health, Inc. notified Odyssey that NeuRX is in breach of its obligations and has cancelled the definitive agreement between the parties. NeuRX alleges it had not obtained required approval from Davion Healthcare Plc before sublicensing the BreastCheck product to Odyssey. The definitive agreement was dated October 14, 2025 and closed on April 21, 2026; the revocation notice was incorporated by reference in Odyssey’s May 11, 2026 8-K.

Key Details

• Notice date: May 6, 2026; Form 8-K filed May 11, 2026.
• Agreement referenced: definitive agreement between Odyssey and NeuRX dated October 14, 2025; closed April 21, 2026.
• Alleged breach: NeuRX failed to obtain Davion Healthcare Plc’s required approval before sublicensing the BreastCheck product and breached representations/warranties that consents had been obtained.
• Result: NeuRX’s notice states the definitive agreement is immediately cancelled.

Why It Matters
This filing concerns Odyssey’s rights to distribute or commercialize the BreastCheck product under the recently closed agreement. The stated cancellation creates legal and commercial uncertainty about Odyssey’s ability to proceed under that deal, which could affect product rollout timelines, potential revenue, and partnership plans. Investors should watch for further disclosures, any legal challenges between the parties, or updates on alternative licensing arrangements.